title: Management of human papilloma virus vulvo-perineal infection with systemic beta-interferon and thymostimulin in HIV-positive patients.
abstract: OBJECTIVE
  To evaluate the effect of a combined therapy based on beta-interferon and thymostimulin in HIV-seropositive women with florid vulvoperineal condylomatosis.
  
  
  METHODS
  Nineteen HIV-seropositive women affected by HPV florid vulvo-perineal infection were studied. Their ages ranged from 19 to 32 years (mean = 26); all were smokers; 11 (57.89%) were intravenous drug users with a mean period of drug addiction of 5 years. No patient was on AZT therapy. All patients underwent a combined medical therapy based on beta-interferon administration with doses of 3,000,000 IU i.m. daily for 7 days and subsequently on alternate days for 2 weeks associated with the administration of 70 mg i.m. of thymostimulin per day on alternate days for 30 days.
  
  
  RESULTS
  Seven (36.84%) patients showed complete recovery at the end of follow-up; 5 (26.31%) patients showed partial recovery and 7 (36.84%) did not respond to therapy.
  
  
  CONCLUSIONS
  A pro-host immunotherapy seems to be indicated in patients affected by immunodeficiency syndrome.
authors.affiliation: II Clinic of Obstetrics and Gynecology, University of Rome La Sapienza, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Frega
authors.forename: F
authors.initials: F
authors.lastname: di Renzi
authors.forename: P
authors.initials: P
authors.lastname: Stentella
authors.forename: A
authors.initials: A
authors.lastname: Pachì
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000382:microbiology / Q000628:therapy*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D003218:Condylomata Acuminata / Q000628:therapy*; D005260:Female; D006679:HIV Seropositivity / Q000382:microbiology*; D006801:Humans; D007369:Interferon Inducers / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use*; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000628:therapy*; D010502:Perineum / Q000382:microbiology; D015819:Substance Abuse, Intravenous / Q000150:complications; D013949:Thymus Extracts / Q000627:therapeutic use*; D014845:Vulvar Diseases / Q000382:microbiology* / Q000628:therapy
chemical_list: D000276:Adjuvants, Immunologic; D007369:Interferon Inducers; D013949:Thymus Extracts; C031407:thymostimulin; D016899:Interferon-beta